Clinical Trial Search

Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 34.0; 47.6 percentage of participants — p==0.049

Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) — 970; 968 picomoles times hour per Liter — p=0.7734

Primary: Numeric Pain Intensity Scale — 3; 3 score on a scale — p=0.39

Primary: Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 — 7.8; 92.3; 88.9 percentage of participants…

Primary: Maximum Tolerated Dose (MTD) of PLX3397 Given in Combination With Standard Dose Eribulin in Participants With Metastatic Breast Cancer (Phase 1b) — 1,000 miligrams per day

Primary: Percentage of Combined Improvement of Depressive Symptoms and CVD Risk Factors — 71.6; 54.7 percentage of participants

Primary: Change From Baseline UDI Total Score — -138.8; -142.7; -137; -147.4 units on a scale

Primary: AUC0-48 — 32.06; 6.491; 45.89; 30.14 ng*hr/mL

Primary: Patients' Safety During Study — 90; 2 Events related to TG01 and /or GM-CSF

Primary: The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to…

Primary: Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline — 62.092; 60.232 percentage of predicted FEV1 — p=0.3264

Primary: Part A: Pharmacokinetics (PK ): Area Under the Concentration Curve From Zero to the Last Recorded Time Post Dose (AUC0-tlast) — 1720; 1740; 1810; 1750 picomol times hour…

Primary: Overall Response Rate (ORR) As Assessed By Independent Review Committee — 72 Participants — p=<.0001

Primary: Number of Subjects Reporting at Least One A/California Influenza Event — 3; 7; 13 Participants

Primary: Clinician Administered PTSD Score (CAPS-5) TSSS — 37.61; 39.82; 25.67; 33.68 score on a scale